cephalosporin c has been researched along with oritavancin in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Roux, A; Lode, H; Schmidt-Ioanas, M | 1 |
| Loffler, CA; Macdougall, C | 1 |
| Micek, ST; Neuner, EA; Ritchie, DJ | 1 |
| Cabeza, J; Carrasco, C; Gutierrez, J; Sorlozano, A; Villegas, E | 1 |
| Kollef, MH | 1 |
| Arhin, FF; Beaulieu, S; Belley, A; McKay, G; Moeck, G; Parr, TR; Sarmiento, I | 1 |
| Wilcox, MH | 1 |
| Holmes, NE; Howden, BP | 1 |
| Raut, A; Rybak, MJ; Smith, JR; Yim, J | 1 |
| Concia, E; Falcone, M; Giusti, M; Mazzone, A; Santini, C; Stefani, S; Violi, F | 1 |
| Hahn, AW; Jain, R; Spach, DH | 1 |
7 review(s) available for cephalosporin c and oritavancin
| Article | Year |
|---|---|
New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient.
Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Clinical Trials as Topic; Critical Illness; Daptomycin; Drug Resistance, Multiple, Bacterial; Glycopeptides; Humans; Linezolid; Lipoglycopeptides; Methicillin Resistance; Minocycline; Oxazolidinones; Staphylococcal Infections; Teicoplanin; Tigecycline; Virginiamycin | 2005 |
New antibiotics for healthcare-associated pneumonia.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Ceftaroline; Cephalosporins; Cross Infection; Doripenem; Glycopeptides; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Pseudomonas Infections; Pyrimidines; Staphylococcal Infections; Teicoplanin | 2009 |
New antimicrobial agents for methicillin-resistant Staphylococcus aureus.
Topics: Aminoglycosides; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Glycopeptides; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Pyrimidines; Staphylococcal Infections; Teicoplanin | 2009 |
MRSA new treatments on the horizon: current status.
Topics: Aminoglycosides; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Glycopeptides; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Skin Diseases, Bacterial; Soft Tissue Infections; Staphylococcal Infections; Teicoplanin | 2011 |
What's new in the treatment of serious MRSA infection?
Topics: Acetamides; Anti-Bacterial Agents; Cephalosporins; Cost-Benefit Analysis; Drug Administration Routes; Drug Therapy, Combination; Glycopeptides; Humans; Linezolid; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Oxazolidinones; Severity of Illness Index; Skin Diseases, Bacterial; Staphylococcal Infections; Tetrazoles; Vancomycin | 2014 |
Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Ceftaroline; Cephalosporins; Daptomycin; Female; Fluoroquinolones; Glycopeptides; Hospitalization; Humans; Iatrogenic Disease; Internal Medicine; Linezolid; Lipoglycopeptides; Male; Minocycline; Oxazolidinones; Skin Diseases, Infectious; Soft Tissue Infections; Teicoplanin; Tigecycline; Vancomycin | 2016 |
New Approaches to Antibiotic Use and Review of Recently Approved Antimicrobial Agents.
Topics: Abdominal Abscess; Anti-Bacterial Agents; Bacterial Infections; Ceftaroline; Cephalosporins; Drug Administration Schedule; Drug Approval; Drug Combinations; Drug Resistance, Microbial; Glycopeptides; Humans; Lipoglycopeptides; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Soft Tissue Infections; Teicoplanin; United States; United States Food and Drug Administration | 2016 |
4 other study(ies) available for cephalosporin c and oritavancin
| Article | Year |
|---|---|
Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections.
Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Clindamycin; Daptomycin; Doxycycline; Folic Acid Antagonists; Global Health; Glycopeptides; Humans; Linezolid; Lipoglycopeptides; Methicillin; Methicillin Resistance; Minocycline; Oxazolidinones; Prevalence; Staphylococcal Infections; Staphylococcus aureus; Sulfamethoxazole; Teicoplanin; Tigecycline; Trimethoprim; Vancomycin | 2007 |
Antimicrobial development in the era of emerging resistance.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Bacteria; beta-Lactams; Cephalosporins; Drug Approval; Drug Resistance, Bacterial; Glycopeptides; Humans; Lipoglycopeptides; Pyrimidines; Skin Diseases, Bacterial; Skin Diseases, Viral; Teicoplanin; United States; United States Food and Drug Administration | 2009 |
Assessment of oritavancin serum protein binding across species.
Topics: Animals; Anti-Bacterial Agents; Blood Proteins; Cefpirome; Cephalosporins; Daptomycin; Dogs; Glycopeptides; Humans; Lipoglycopeptides; Mice; Microbial Sensitivity Tests; Protein Binding; Rats; Species Specificity; Staphylococcus aureus | 2010 |
Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefazolin; Ceftaroline; Cephalosporins; Daptomycin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Ertapenem; Glycopeptides; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Nafcillin; Staphylococcal Infections; Vancomycin; Vancomycin-Resistant Enterococci | 2016 |